Table 3.

Results of regression analyses relating severity at the first intervention contact to trialarm and severity at intake interview adjusting for the number of days between intake interviewand first intervention contact.

	Pain			Fatigue			Peripheral Neuropathy
	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value
Intake severity	0.14	78.0	<0.0001	0.10	94.9	<0.0001	0.18	179.3	<0.0001
Trial Arm	0.25	8.1	0.0045^*	0.12	4.8	0.0290	0.15	5.6	0.0182
	Cough			Dyspnea			Insomnia
	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value
Intake severity	0.19	135.4	<0.0001	0.17	140.5	<0.0001	0.12	102.2	<0.0001
Trial Arm	0.05	0.7	0.4085	0.15	5.2	0.0223	0.02	0.04	0.8395
	Dry Mouth			Alopecia			Difficulty Remembering
	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value
Intake severity	0.12	80.8	<0.0001	0.08	34.5	<0.0001	0.17	125.8	<0.0001
Trial Arm	-0.09	1.3	0.25	0.42	23.2	<0.0001^**	-0.08	1.3	0.2594
	Poor Appetite			Nausea/Vomiting			Diarrhea
	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value
Intake severity	0.12	98.3	<0.0001	0.14	106.2	<0.0001	0.11	72.2	<0.0001
Trial Arm	0.22	9.1	0.0027^**	0.33	21.2	<0.0001^**	0.19	8.1	0.0046^*
	Constipation			Weakness
	Beta	Wald χ²	P-value	Beta	Wald χ²	P-value
Intake severity	0.12	89.1	<0.0001	0.13	109.8	<0.0001
Trial Arm	0.35	22.0	<0.0001^**	0.11	2.3	0.1327

Statistically significant according to Benjamini-Hochberg procedure

^**

Statistically significant according to Bonferroni procedure (all comparisons that are significant with Bonferroni procedure are also significant with Benjamini-Hochberg procedure)